Three pharmaceutical companies are launched to develop generic drugs of Iressa which costs about 30 billion won
Three domestic pharmaceutical companies are being competitive for the development generic lung cancer drug.
On 29th according to MFDS, there are three generic developing companies which have passed bioequivalence Test(BE Test) for gefinitib
Gefinitib is a main component of Iressa, and CKD, Ildo...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
